HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation

Table 9 Data on human leukocyte antigen mismatches on the risk of acute cellular rejection after liver transplantation, according to primary sclerosing cholangitis or non-primary sclerosing cholangitis n (%)

Locus	MM	Non-AR group	AR group	P value
	(n)	(PSC, n = 26)	(PSC) n = 17)
		(Non-PSC, n = 76)	(Non-PSC) n = 24)
HLA-A
(PSC)	1-2	20 (57.1)	15 (42.9)	0.35
	0	6 (75.0)	2 (25.0)
(non-PSC)	1-2	65 (73.9)	23 (26.1)	0.18
	0	11 (92.7)	1 (7.3)
HLA-B
(PSC)	1-2	25 (59.5)	17 (40.5)	0.41
	0	1 (100.0)	0 (0.0)
(non-PSC)	1-2	73 (75.3)	24 (24.7)	0.32
	0	3 (100.0)	0 (0.0)
HLA-DR
(PSC)	1-2	26 (61.9)	16 (38.1)	0.44
	0	0 (0.0)	1 (100.0)
(non-PSC)	1-2	67 (74.4)	23 (25.6)	0.27
	0	9 (90.0)	1 (10.0)
A, B, DR
(PSC)	5-6	12 (54.5)	10 (45.5)	0.42
	0-4	14 (66.7)	7 (33.3)
(non-PSC)	5-6	29 (67.4)	14 (32.6)	0.08
	0-4	47 (82.4)	10 (17.6)

Uncorrected P values were calculated by the χ² test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; PSC: Primary sclerosing cholangitis; MM: mismatches; AR: acute cellular rejection.